This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cotterill, S.J. Articles by Craft, A.W. Search for Related Content PubMed PubMed Citation Articles by Cotterill, S.J. Articles by Craft, A.W. Social Bookmarking                            What's this?

Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group

From the Institute of Child Health, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; The University of Münster, Münster, Germany; The Emma Kinder Ziekenhuis Academic Medical Center, Amsterdam, the Netherlands; and The St. Anna Children’s Hospital, Vienna, Austria.

Address reprint requests to S.J. Cotterill, MD, Research Associate, Institute of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, United Kingdom; email S.J.Cotterill{at}ncl.ac.uk

PURPOSE: To further elaborate on prognostic factors for Ewing’s sarcoma of bone and to document improvements in relapse-free survival (RFS) and trends in local therapy over the study period (1977 to 1993).

PATIENTS AND METHODS: A retrospective analysis was performed on a combined Gesellschaft Für Pädiatrische Onkologie und Hämatologie/Cooperative Ewing Sarcoma Study and United Kingdom Children’s Cancer Study Group/Medical Research Council data set of 975 patients registered with the respective trial offices before the current collaborative European Intergroup Cooperative Ewing’s Sarcoma Study trial. Both groups independently undertook studies with similar chemotherapy during the period.

RESULTS: The key adverse prognostic factor is metastases at diagnosis (5-year RFS, 22% of patients with metastases at diagnosis v 55% of patients without metastases at diagnosis; P < .0001). For the group with metastases, there was a trend for better survival for those with lung involvement compared with those with bone metastases or a combination of lung and bone metastases (P < .0001). In the group of patients with no metastases at diagnosis, multivariate analysis demonstrated that site (axial v other), age-group (< 15 v 15 years), and period of diagnosis had significant influence on RFS (all P < .005). RFS was superior in the period after 1985 compared with the period before 1985 for nonmetastatic patients (45% v 60%, respectively; P < .0001) and for metastatic patients (16% v 30%, respectively; P = .016). Patients who relapsed within 2 years of diagnosis had a less favorable prognosis than patients who relapsed later (5-year survival after relapse, 4% v 23%, respectively; P < .0001). There were other changes over the period; in particular, radiotherapy or amputation were more common in the period before 1986, whereas endoprosthetic surgery was widely used in the later period.

CONCLUSION: Survival and RFS improved over the period. Prognostic factors are metastases at diagnosis, primary site, and age.

S.J.C. was supported by the North of England Children’s Cancer Research Fund.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Scotlandi, D. Remondini, G. Castellani, M. C. Manara, F. Nardi, L. Cantiani, M. Francesconi, M. Mercuri, A. M. Caccuri, M. Serra, et al. Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome J. Clin. Oncol., May 1, 2009; 27(13): 2209 - 2216. [Abstract] [Full Text] [PDF]

				M. Paulussen, S. Bielack, H. Jurgens, P. G. Casali, and On behalf of the ESMO Guidelines Working Group Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv140 - iv142. [Full Text] [PDF]

				K. Kikuta, N. Tochigi, T. Shimoda, H. Yabe, H. Morioka, Y. Toyama, A. Hosono, Y. Beppu, A. Kawai, S. Hirohashi, et al. Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics Clin. Cancer Res., April 15, 2009; 15(8): 2885 - 2894. [Abstract] [Full Text] [PDF]

				A. H. Krieg, M. Mani, B. M. Speth, and P. D. Stalley Extracorporeal irradiation for pelvic reconstruction in Ewing's sarcoma J Bone Joint Surg Br, March 1, 2009; 91-B(3): 395 - 400. [Abstract] [Full Text] [PDF]

				O. A. ANAKWENZE, W. L. PARKER, L. E. WOLD, K. K AMRAMI, and P. C. AMADIO Ewing's Sarcoma of the Hand J Hand Surg Eur Vol., February 1, 2009; 34(1): 35 - 39. [Abstract] [Full Text] [PDF]

				C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas Clin. Cancer Res., August 1, 2008; 14(15): 4850 - 4858. [Abstract] [Full Text] [PDF]

				Image of the Month--Diagnosis Arch Surg, May 1, 2008; 143(5): 512 - 512. [Full Text] [PDF]

				M. van Kampen, R. J. Grimer, S. R. Carter, R. M. Tillman, and A. Abudu Replacement of the Hip in Children with a Tumor in the Proximal Part of the Femur J. Bone Joint Surg. Am., April 1, 2008; 90(4): 785 - 795. [Abstract] [Full Text] [PDF]

				C. Rodriguez-Galindo, F. Navid, T. Liu, C. A. Billups, B. N. Rao, and M. J. Krasin Prognostic factors for local and distant control in Ewing sarcoma family of tumors Ann. Onc., April 1, 2008; 19(4): 814 - 820. [Abstract] [Full Text] [PDF]

				H. U. Gerth, K. U. Juergens, U. Dirksen, J. Gerss, O. Schober, and C. Franzius Significant Benefit of Multimodal Imaging: PET/CT Compared with PET Alone in Staging and Follow-up of Patients with Ewing Tumors J. Nucl. Med., December 1, 2007; 48(12): 1932 - 1939. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				G. Bacci, A. Balladelli, C. Forni, A. Longhi, M. Serra, N. Fabbri, M. Alberghini, S. Ferrari, M. S. Benassi, and P. Picci Ewing's sarcoma family tumours: DIFFERENCES IN CLINICOPATHOLOGICAL CHARACTERISTICS AT PRESENTATION BETWEEN LOCALISED AND METASTATIC TUMOURS J Bone Joint Surg Br, September 1, 2007; 89-B(9): 1229 - 1233. [Abstract] [Full Text] [PDF]

				H. S. Hosalkar and J. P. Dormans Surgical Management of Pelvic Sarcoma in Children J. Am. Acad. Ortho. Surg., July 1, 2007; 15(7): 408 - 424. [Abstract] [Full Text] [PDF]

				A. S.K. de Hooge, D. Berghuis, S. J. Santos, E. Mooiman, S. Romeo, J. A. Kummer, R. M. Egeler, M. J.D. van Tol, C. J.M. Melief, P. C.W. Hogendoorn, et al. Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways Clin. Cancer Res., January 1, 2007; 13(1): 206 - 214. [Abstract] [Full Text] [PDF]

				R. K. Heck Jr., T. D. Peabody, and M. A. Simon Staging of Primary Malignancies of Bone CA Cancer J Clin, November 1, 2006; 56(6): 366 - 375. [Abstract] [Full Text] [PDF]

				O. Oberlin, A. Rey, A. S. Desfachelles, T. Philip, D. Plantaz, C. Schmitt, E. Plouvier, O. Lejars, H. Rubie, P. Terrier, et al. Impact of High-Dose Busulfan Plus Melphalan As Consolidation in Metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l'Enfant J. Clin. Oncol., August 20, 2006; 24(24): 3997 - 4002. [Abstract] [Full Text] [PDF]

				A. McTiernan, D. Driver, M. P. Michelagnoli, A. M. Kilby, and J. S. Whelan High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours Ann. Onc., August 1, 2006; 17(8): 1301 - 1305. [Abstract] [Full Text] [PDF]

				M. Bernstein, H. Kovar, M. Paulussen, R. L. Randall, A. Schuck, L. A. Teot, and H. Juergensg Ewing's Sarcoma Family of Tumors: Current Management. Oncologist, May 1, 2006; 11(5): 503 - 519. [Abstract] [Full Text] [PDF]

				M. L. Bernstein, M. Devidas, D. Lafreniere, A.-K. Souid, P. A. Meyers, M. Gebhardt, K. Stine, R. Nicholas, E. J. Perlman, R. Dubowy, et al. Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--A Report From the Children's Oncology Group J. Clin. Oncol., January 1, 2006; 24(1): 152 - 159. [Abstract] [Full Text] [PDF]

				M. Scurr and I. Judson How to Treat the Ewing's Family of Sarcomas in Adult Patients Oncologist, January 1, 2006; 11(1): 65 - 72. [Abstract] [Full Text] [PDF]

				D. S. Hawkins, S. M. Schuetze, J. E. Butrynski, J. G. Rajendran, C. B. Vernon, E. U. Conrad III, and J. F. Eary [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors J. Clin. Oncol., December 1, 2005; 23(34): 8828 - 8834. [Abstract] [Full Text] [PDF]

				L. M. Barker, T. W. Pendergrass, J. E. Sanders, and D. S. Hawkins Survival After Recurrence of Ewing's Sarcoma Family of Tumors J. Clin. Oncol., July 1, 2005; 23(19): 4354 - 4362. [Abstract] [Full Text] [PDF]

				M. R. Verneris, A. Arshi, M. Edinger, M. Kornacker, Y. Natkunam, M. Karami, Y.-a. Cao, N. Marina, C. H. Contag, and R. S. Negrin Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells Clin. Cancer Res., June 15, 2005; 11(12): 4561 - 4570. [Abstract] [Full Text] [PDF]

				S. S. Myatt, C. P.F. Redfern, and S. A. Burchill p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death Clin. Cancer Res., April 15, 2005; 11(8): 3136 - 3148. [Abstract] [Full Text] [PDF]

				S. Dalal, A. M. Berry, C. J. Cullinane, D. C. Mangham, R. Grimer, I. J. Lewis, C. Johnston, V. Laurence, and S. A. Burchill Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family Clin. Cancer Res., March 15, 2005; 11(6): 2364 - 2378. [Abstract] [Full Text] [PDF]

				H. Guan, S.-F. Jia, Z. Zhou, J. Stewart, and E. S. Kleinerman Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo Clin. Cancer Res., March 1, 2005; 11(5): 2008 - 2017. [Abstract] [Full Text] [PDF]

				A. Argon, M. Basaran, F. Yaman, Y. Dizdar, B. Sakar, H. Camlica, S. E. Bavbek, H. Ozger, E. Darendeliler, and H. Onat Ewing's Sarcoma of the Axial System in Patients Older Than 15 Years: Dismal Prognosis Despite Intensive Multiagent Chemotherapy and Aggressive Local Treatment Jpn. J. Clin. Oncol., November 1, 2004; 34(11): 667 - 672. [Abstract] [Full Text] [PDF]

				A. Eroglu, I. C. Kurkcuoglu, N. Karaoglanoglu, F. Alper, and C. Gundogdu Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax Ann. Thorac. Surg., August 1, 2004; 78(2): 715 - 717. [Abstract] [Full Text] [PDF]

				E. A. Kolb, B. H. Kushner, R. Gorlick, C. Laverdiere, J. H. Healey, M. P. LaQuaglia, A. G. Huvos, J. Qin, H. T. Vu, L. Wexler, et al. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults J. Clin. Oncol., September 15, 2003; 21(18): 3423 - 3430. [Abstract] [Full Text] [PDF]

				S. Burdach, A. Meyer-Bahlburg, H.J. Laws, R. Haase, B. van Kaik, B. Metzner, A. Wawer, R. Finke, U. Gobel, J. Haerting, et al. High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing's Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation J. Clin. Oncol., August 15, 2003; 21(16): 3072 - 3078. [Abstract] [Full Text] [PDF]

				G. Saeter ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Ewing's sarcoma of bone Ann. Onc., August 1, 2003; 14(8): 1167 - 1168. [Full Text] [PDF]

				C. M. L. da Costa, A. Lopes, and B. de Camargo A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing's tumor into low and high risk Ann. Onc., April 1, 2003; 14(4): 656 - 656. [Full Text] [PDF]

				K. Kimura, S. Tatezaki, T. Ishii, T. Yonemoto, T. Shigehara, and T. Takenouchi Hemiarthroplasty of the Elbow with a Vascularized Fibular Graft after Excision of Ewing's Sarcoma of the Proximal Ulna: a Case Report Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 430 - 434. [Abstract] [Full Text] [PDF]

				C. P. Gibbs Jr., K. Weber, and M. T. Scarborough Malignant Bone Tumors J. Bone Joint Surg. Am., November 1, 2001; 83(11): 1728 - 1745. [Full Text] [PDF]

				M. C. Gebhardt What's New in Musculoskeletal Tumor Surgery J. Bone Joint Surg. Am., April 1, 2001; 83(4): 629 - 629. [Full Text]